<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04891406</url>
  </required_header>
  <id_info>
    <org_study_id>IB-OND-PKZX-01</org_study_id>
    <nct_id>NCT04891406</nct_id>
  </id_info>
  <brief_title>Nicotine Delivery From Oral Tobacco Products</brief_title>
  <official_title>A Randomised, Cross-over, Relative Bioavailability Study of Nicotine Delivery and Nicotine Extraction From Oral Tobacco Products (Traditional Snus, Conventional Cigarette and Three Oral Tobacco-free Nicotine Delivery Products)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Imperial Brands PLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Imperial Brands PLC</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a randomised cross-over, open-label, confinement study conducted in 24 male or&#xD;
      female snus and cigarette consumers. The study investigates 5 different nicotine containing&#xD;
      products in a cross-over fashion. The study incorporates pharmacokinetics evaluation,&#xD;
      nicotine extraction evaluation, subjective questionnaire assessments as well as safety&#xD;
      evaluation.&#xD;
&#xD;
      During the study participation, subjects come for two visits to the clinic, including a 5-day&#xD;
      confinement period.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 1, 2020</start_date>
  <completion_date type="Actual">January 20, 2021</completion_date>
  <primary_completion_date type="Actual">January 20, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Nicotine Cmax</measure>
    <time_frame>Pre-use and at 2, 5, 7, 15, 20, 30, 45, 60, 90 minutes, and 2, 4, 6 and 8 hours post use start</time_frame>
    <description>Maximum plasma concentration of nicotine (Cmax)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Nicotine AUCt</measure>
    <time_frame>Pre-use and at 2, 5, 7, 15, 20, 30, 45, 60, 90 minutes, and 2, 4, 6 and 8 hours post use start</time_frame>
    <description>Area under the plasma nicotine concentration-time curve at the last timepoint measured (AUCt)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Nicotine extraction</measure>
    <time_frame>20 minutes</time_frame>
    <description>Extraction fraction (%) of nicotine in used product pouches after 20 minutes of use</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>From the start of product use until the end-of-study visit (Day 7)</time_frame>
    <description>Incidence of adverse events (AEs) and serious adverse events (SAEs)</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>ZoneX#2 - ZoneX#3 - Skruf - Swave - Cigarette (sequence order ABCDE)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Subjects use product A (ZoneX #2, white tobacco-free nicotine pouch, 5.8 mg nicotine/pouch) for 20 minutes on Day 1, then switch to use product B (ZoneX #3, white tobacco-free nicotine pouch, 10.1 mg nicotine/pouch) for 20 min on Day 2, then product C (Skruf snus fresh slim white, 10.9 mg nicotine/pouch) for 20 min on Day 3, then D (Swave Daquiri, nicotine pouch, 10.6 mg/pouch) on Day 4 and finally E (Marlboro Gold, conventional cigarette, 0.8 mg nicotine/cigarette), smoked in approximately 5 minutes with puffs taken at regular intervals approximately 30 seconds apart, on Day 5.&#xD;
Subjects can use their assigned product ad libitum on each study day, after all study assessments are performed, until 10pm. A washout period of product abstinence is observed between products, overnight.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ZoneX#3 - Skruf - Swave - Cigarette - ZoneX#2 (sequence order BCDEA)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Same as previous arm but in a different randomization order.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Skruf - Swave - Cigarette - ZoneX#2 - ZoneX#3 (sequence order CDEAB)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Same as previous arm but in a different randomization order.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Swave - Cigarette - ZoneX#2 - ZoneX#3 - Skruf (sequence order DEABC)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Same as previous arm but in a different randomization order.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cigarette - ZoneX#2 - ZoneX#3 - Skruf - Swave (sequence order EABCD)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Same as previous arm but in a different randomization order.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>ZoneX#2</intervention_name>
    <description>Use of product A (ZoneX #2, white tobacco-free nicotine pouch, 5.8 mg nicotine/pouch) for 20 minutes</description>
    <arm_group_label>Cigarette - ZoneX#2 - ZoneX#3 - Skruf - Swave (sequence order EABCD)</arm_group_label>
    <arm_group_label>Skruf - Swave - Cigarette - ZoneX#2 - ZoneX#3 (sequence order CDEAB)</arm_group_label>
    <arm_group_label>Swave - Cigarette - ZoneX#2 - ZoneX#3 - Skruf (sequence order DEABC)</arm_group_label>
    <arm_group_label>ZoneX#2 - ZoneX#3 - Skruf - Swave - Cigarette (sequence order ABCDE)</arm_group_label>
    <arm_group_label>ZoneX#3 - Skruf - Swave - Cigarette - ZoneX#2 (sequence order BCDEA)</arm_group_label>
    <other_name>Product A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>ZoneX#3</intervention_name>
    <description>Use of product B (ZoneX #3, white tobacco-free nicotine pouch, 10.1 mg nicotine/pouch) for 20 minutes</description>
    <arm_group_label>Cigarette - ZoneX#2 - ZoneX#3 - Skruf - Swave (sequence order EABCD)</arm_group_label>
    <arm_group_label>Skruf - Swave - Cigarette - ZoneX#2 - ZoneX#3 (sequence order CDEAB)</arm_group_label>
    <arm_group_label>Swave - Cigarette - ZoneX#2 - ZoneX#3 - Skruf (sequence order DEABC)</arm_group_label>
    <arm_group_label>ZoneX#2 - ZoneX#3 - Skruf - Swave - Cigarette (sequence order ABCDE)</arm_group_label>
    <arm_group_label>ZoneX#3 - Skruf - Swave - Cigarette - ZoneX#2 (sequence order BCDEA)</arm_group_label>
    <other_name>Product B</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Skruf</intervention_name>
    <description>Use of product C (Skruf snus fresh slim white, 10.9 mg nicotine/pouch) for 20 minutes</description>
    <arm_group_label>Cigarette - ZoneX#2 - ZoneX#3 - Skruf - Swave (sequence order EABCD)</arm_group_label>
    <arm_group_label>Skruf - Swave - Cigarette - ZoneX#2 - ZoneX#3 (sequence order CDEAB)</arm_group_label>
    <arm_group_label>Swave - Cigarette - ZoneX#2 - ZoneX#3 - Skruf (sequence order DEABC)</arm_group_label>
    <arm_group_label>ZoneX#2 - ZoneX#3 - Skruf - Swave - Cigarette (sequence order ABCDE)</arm_group_label>
    <arm_group_label>ZoneX#3 - Skruf - Swave - Cigarette - ZoneX#2 (sequence order BCDEA)</arm_group_label>
    <other_name>Product C</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Swave</intervention_name>
    <description>Use of product D (Swave Daquiri, nicotine pouch, 10.6 mg/pouch) for 20 minutes</description>
    <arm_group_label>Cigarette - ZoneX#2 - ZoneX#3 - Skruf - Swave (sequence order EABCD)</arm_group_label>
    <arm_group_label>Skruf - Swave - Cigarette - ZoneX#2 - ZoneX#3 (sequence order CDEAB)</arm_group_label>
    <arm_group_label>Swave - Cigarette - ZoneX#2 - ZoneX#3 - Skruf (sequence order DEABC)</arm_group_label>
    <arm_group_label>ZoneX#2 - ZoneX#3 - Skruf - Swave - Cigarette (sequence order ABCDE)</arm_group_label>
    <arm_group_label>ZoneX#3 - Skruf - Swave - Cigarette - ZoneX#2 (sequence order BCDEA)</arm_group_label>
    <other_name>Product D</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Marlboro Gold</intervention_name>
    <description>Use of product E (Marlboro Gold, conventional cigarette, 0.8 mg nicotine/cigarette) for approximately 5 minutes</description>
    <arm_group_label>Cigarette - ZoneX#2 - ZoneX#3 - Skruf - Swave (sequence order EABCD)</arm_group_label>
    <arm_group_label>Skruf - Swave - Cigarette - ZoneX#2 - ZoneX#3 (sequence order CDEAB)</arm_group_label>
    <arm_group_label>Swave - Cigarette - ZoneX#2 - ZoneX#3 - Skruf (sequence order DEABC)</arm_group_label>
    <arm_group_label>ZoneX#2 - ZoneX#3 - Skruf - Swave - Cigarette (sequence order ABCDE)</arm_group_label>
    <arm_group_label>ZoneX#3 - Skruf - Swave - Cigarette - ZoneX#2 (sequence order BCDEA)</arm_group_label>
    <other_name>Product E</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Body Mass Index (BMI) ≥ 18.0 and ≤ 30.0 kg/m&#xD;
&#xD;
          -  Clinically normal medical history, physical findings, vital signs, ECG and laboratory&#xD;
             values at the time of screening, as judged by the Investigator&#xD;
&#xD;
          -  Dual user of snus and conventional cigarettes for ≥1 year, with a minimum weekly&#xD;
             consumption of two or more snus cans and &gt;5 cigarettes, and who is willing and able to&#xD;
             use brands with nicotine content ≥1%&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of any clinically significant disease or disorder&#xD;
&#xD;
          -  Any clinically significant illness, medical/surgical procedure or trauma within 4&#xD;
             weeks of the first use of IP&#xD;
&#xD;
          -  Positif for HIV, hepatitis B or C&#xD;
&#xD;
          -  After 10 minutes supine rest at the time of screening, any vital signs values outside&#xD;
             the following ranges:&#xD;
&#xD;
               -  Systolic blood pressure &lt;90 or &gt;140 mmHg, or&#xD;
&#xD;
               -  Diastolic blood pressure &lt;50 or &gt;90 mmHg, or&#xD;
&#xD;
               -  Pulse &lt;40 or &gt;90 bpm&#xD;
&#xD;
          -  Alcohol or drug abuse&#xD;
&#xD;
          -  Use, or history of use of anabolic steroids&#xD;
&#xD;
          -  Allergy/hypersensitivity to drugs with a similar chemical structure or class to&#xD;
             nicotine&#xD;
&#xD;
          -  Excessive caffeine consumption (daily intake of &gt;5 cups)&#xD;
&#xD;
          -  Female subjects who are pregnant or breastfeeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>CTC Clinical Trial Consultants AB (CTC)</name>
      <address>
        <city>Uppsala</city>
        <zip>SE-752 37</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 12, 2021</study_first_submitted>
  <study_first_submitted_qc>May 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 18, 2021</study_first_posted>
  <last_update_submitted>May 17, 2021</last_update_submitted>
  <last_update_submitted_qc>May 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

